GSK Pharmaceutical Industry
Fellowship Program
2024-2026
GSK is proud to partner with University of North Carolina (UNC) Eshelman School of Pharmacy to offer 2-year fellowship programs, aiming to develop pharmaceutical industry professionals to become successful leaders and innovators.

Our goal is to provide the opportunity for fellows to gain the skills, knowledge, and experience needed to pursue a career in the pharmaceutical industry, enabling them to become successful leaders and innovators. Fellows develop a strong scientific foundation in areas of interest by gaining practical experience in the pharmaceutical drug development setting and applying those learnings for the advancement of pharmaceutical sciences.

GSK has a rich history of collaborations with a variety of leading academic institutions through sponsorship of joint fellowship programs.

Fellowships offered by GSK in partnership with UNC Eshelman School of Pharmacy include:

- **Global Regulatory Affairs**
  - (PharmD, PhD, or MD)

- **Pharmacokinetics/Pharmacodynamics**
  - (PharmD, PhD, or MD)

- **US Medical Affairs**
  - (PharmD or PhD)

- **Global Pharmacovigilance**
  - (PharmD, PhD, or MD)
Today there are millions of people without access to basic healthcare, thousands of diseases without adequate treatments and millions of people who suffer from everyday ailments. We want to change this. That’s why we are harnessing our scientific and technical know-how, our talented people, our partnerships, and our global reach to develop and manufacture healthcare products for people who need them.

Our mission is to improve the quality of human life by enabling people to do more, feel better, and live longer.
GSK at a glance

Who we are

We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together.

We aim to positively impact the health of 2.5 billion people by the end of 2030, with ambitious plans for growth and continuing to make GSK a company where everyone can thrive.

What we do

We prioritise innovation in vaccines and specialty medicines to prevent and treat disease.

In 2022:

- £29.3bn medicines and vaccine sales
- £5.5bn R&D investment
- 18 pipeline assets in phase III/registration
- 7 new collaborations and acquisitions
- 1.85bn packs of medicines and vaccine doses delivered

Our priorities

Innovation
Finding new vaccines and medicines to tackle unmet needs. With better, faster and smarter R&D. Combining the power of genetic and genomic insights into the causes of disease, with the speed and scale of artificial intelligence and machine learning.

Performance
New commitments to growth and a significant step-change in performance. So that more GSK vaccines and medicines than ever before – including innovative new products – reach the people who need them most.

Trust
Delivering our strategy responsibly, always considering the social, environmental and governance impacts of everything we do. Working together in six areas where we can make a difference: pricing and access; global health and health security; diversity, equity and inclusion; environmental sustainability; product governance and ethical standards.

In 2022:

- 18 pipeline assets in phase III/registration
- 7 new collaborations and acquisitions
- £29.3bn medicines and vaccine sales
- 1.85bn packs of medicines and vaccine doses delivered
- 1st in the Access to Medicine Index
- 2nd in our industry for the S&P Global Corporate Sustainability Assessment

Our culture

We have over 70,000 people in more than 80 countries worldwide and culture at GSK is something we all own.

We are ambitious for patients to deliver what matters better and faster
We are accountable for impact with clear ownership and support to succeed
We do the right thing with integrity and care because people count on us

This powers our purpose, drives delivery of our strategy, and helps make GSK a place where people can thrive.

These are the foundations for how, together, we will deliver more for our patients, shareholders and GSK people.

Why we do it

We aim to get ahead of disease together – to positively impact the health of 2.5 billion people by the end of 2030.

Our portfolio:

Vaccines
Our unrivalled portfolio targets infectious diseases at every stage of life helping protect people from shingles, meningitis, flu, polio, measles and many more.

Specialty Medicines
We are global leaders in HIV medicines, pioneering new long-acting therapies and HIV prevention. We focus on life-changing cancer medicines and novel treatments for other immune-mediated diseases.

General Medicines
From inhaled medicines for asthma and COPD to antibiotics to medicines for skin diseases, we make life better for millions of people in over 112 countries.

Ahead Together
The UNC Eshelman School of Pharmacy, ranked as the #1 pharmacy school in the nation by the US News and World Report 2020, is a nationally recognized leader in progressive pharmaceutical care practice, education, and research. We are committed to building a diverse talent pipeline. Our global inclusion and diversity councils are driving our agenda.

“Each year, for more than four decades, we have an incredible group of fellows, who make a significant contribution to the legacy of our program. These fellows are a reflection of UNC and GSK’s strong long-standing commitment to train and develop the newest generation of pharmaceutical industry professionals.”

Robert Dupuis, Pharm.D, FCCP
Professor, Division of Pharmacotherapy and Experimental Therapeutics
Director of Fellowship Programs

Derek Bartlett, Ph.D.
Assistant Professor, Division of Pharmacotherapy and Experimental Therapeutics
UNC

Yanguang (Carter) Cao, Ph.D.
Associate Professor, Division of Pharmacotherapy and Experimental Therapeutics
UNC

Julie Dumond, Pharm.D, M.S.
Associate Professor, Division of Pharmacotherapy and Experimental Therapeutics
UNC

The Eshelman School of Pharmacy is part of the University of North Carolina at Chapel Hill, a major research university with a large academic medical center. The School of Pharmacy has specialized research centers Pursuing advancements in drug delivery, nanotechnology, cancer treatment, pharmacogenomics, and medication optimization.

UNC anchors one corner of North Carolina’s famed RTP which hosts an abundance of pharmaceutical, biotechnology, and healthcare companies. This environment offers opportunities for collaboration in research, education, and patient care with partners in academia, industry, and healthcare. Durham is the largest GSK commercial site that operates in the US and houses Critical roles in pharmaceuticals, corporate, and manufacturing functions, as well as Research and Development (R&D) and ViiV Healthcare.

US Medical Affairs and PK/PD fellows gain pharmaceutical industry experience during the second year of the fellowship program at Durham. Global Regulatory Affairs fellows spend 2 years with their sponsor company. Global Pharmacovigilance fellows spend time over both years at Durham.

The Upper Providence GSK site, which is the US R&D Hub, is named for its location in Upper Providence Township, Montgomery County, Pennsylvania. It is approximately 30 miles northwest of Center City Philadelphia and approximately 35 miles from Philadelphia International Airport.

At UP, GRA and PK/PD fellows gain hands-on pharmaceutical industry experience in a highly dynamic work environment.
US Medical Affairs Fellowship

Fellows have a unique opportunity to gain practical experience in the clinical drug development setting and apply those learnings within medical affairs at GSK. Fellows gain the practical training and experience to pursue a career in the pharmaceutical industry, academia, clinical practice or with a contract research organization.

Fellows collaborate cross-functionally with US Senior Medical Affairs Leads, Scientific Directors, Scientific Training Directors, Medical Capabilities Directors and Field Medical Liaisons in support of the overall medicine plan. Fellows make impactful contributions to the business as they learn and develop professionally during their fellowship journey.

Fellowship Objectives

- Understand the role of Medical Affairs in the pharmaceutical industry working closely with the US Senior Medical Affairs Lead and collaborating cross-functionally for a medicine in support of the overall medicine plan
- Understand principles of clinical research, apply clinical trial designs and strategy, and collect and analyze data
- Conduct strategic reviews of the medical literature and the competitive environment to identify data and educational gaps to enhance patient care
- Contribute to US scientific engagement between GSK and external communities to advance the understanding of disease and management
- Participate in the medical review of promotional materials and communicate scientific information to internal and field based colleagues
- Support launch preparations for new medicines and/or new indications or label extensions

Preceptors

- Kelly Pincus, PharmD
  US Medical Affairs, Senior Director & Head Medical Communications & Scientific Training, Oncology
- Jacqueleen Collins, PharmD
  Director, Medical Communications and Scientific Training, Strategy and Operations
- George Clayton, PharmD
  Director, Medical Capabilities and Learning Excellence
- Bryant Tan, PharmD, MBA
  Scientific Director, Specialty Pipeline, Pipeline Innovation

Fellows

- Christopher Randall, PharmD
  Second Year Fellow, Mercer University College of Pharmacy
- James Caless, PharmD
  Second Year Fellow, UNC Eshelman School of Pharmacy
- Antoinette Burgess, PharmD
  Head, Medical Engagement and Capabilities
- Maurika Upchurch, PharmD
  First Year Fellow, Mercer University College of Pharmacy
- Eugene Lee, PharmD
  First Year Fellow, Northeastern University School of Pharmacy

Year 1

At the UNC Eshelman School of Pharmacy, fellows will have the opportunity to

- Review the principles of clinical research, such as Good Clinical Practice (GCP) and gain an understanding of the wellbeing of study subjects, data collection, analysis, and safety reporting
- Apply clinical design strategies, evaluate research designs and study reports, and utilize biostatistical tests
- Develop protocols; recruit and monitor subjects, collect and analyze data, and prepare an academic manuscript

Year 2

GSK within US Medical Affairs, fellows will have the opportunity to

- Understand the decision-making process that healthcare providers and payers follow for drug utilization
- Contribute to the development and execution of US Medical Affairs plans and integrate the voice of the customer including, providers, payers, patients, into a medical affairs strategy
- Gain clinical knowledge and product expertise in a therapeutic area

Program Director

- Antoinette Burgess, PharmD
  Head, Medical Engagement and Capabilities

"The partnership between UNC and GSK on these fellowship opportunities provides a unique and exciting development opportunity. Fellows gain practical experiences within the drug development and clinical trial pipeline and perform university setting and then apply these learnings within the pharmaceutical industry setting in US Medical Affairs. Our Fellows make a significant contribution as they speak on their journey with us and help to shape their overall professional careers."
Global Regulatory Affairs Fellowship

The Global Regulatory Affairs (GRA) fellowship provides practical training and experience to help fellows gain expertise in regulatory requirements and strategy pertinent to drug development.

Fellows will develop an in-depth understanding of regulatory affairs and the drug development process from pre-clinical to post-marketing strategies. Fellows will establish a strong foundation of experience and knowledge to lead a successful career within the pharmaceutical industry, Food and Drug Administration (FDA), or Contract Research Organizations (CRO).

Fellowship Objectives

• Develop regulatory strategy by using and interpreting regulations and guidelines
• Provide support to the life-cycle management activities pre- and post-approval, for drug and biologic products and gain an understanding of the principles of agency review processes
• Gain an understanding of early and late phase clinical development and gain expertise in the requirements of regulatory submissions
• Understand the various facets of global regulatory affairs, including labeling, advertising and promotion, regulatory intelligence, chemistry manufacturing and controls (CMC), and non-clinical regulatory
• Participate in departmental initiatives for process improvements and/or regulatory knowledge management
• Obtain valuable foundational knowledge by partaking in the Regulatory Affairs Certification (RAC) course and examination.

Global Regulatory Affairs (GRA) fellows may be based out of Upper Providence, PA, throughout the 2-year duration of the fellowship program. GSK will recruit at least 2 qualified post-doctoral Regulatory Affairs fellow candidates to support either Therapeutic Groups (Regulatory Strategy), including Oncology, or Chemistry, Manufacturing & Controls (CMC). Candidates should identify which position is of interest.

Therapeutic Groups (TG)
The TG fellow will have the opportunity to:
• Become an integrated member of the cross-functional team and provide regulatory strategic input for both early and late-stage clinical development programs
• Interact with health authorities globally through correspondences and preparation of submission packages to guide product development
• Develop and maintain awareness of the regulatory landscape to inform drug development

Chemistry, Manufacturing & Controls (CMC)
The CMC fellow will have the opportunity to:
• Liaise with health authorities to obtain scientific advice and respond to CMC questions
• Collaborate with a variety of functional areas, such as biopharmaceutical development and supply, manufacturing, device engineering, quality, and clinical, to determine overall CMC regulatory strategy for biopharmaceuticals/cell gene therapy (CGT)
• Plan/prepare CMC Biopharmaceuticals regulatory documents for global submissions across all stages of product development and life cycle
• Support health authority engagements related to scientific advice and CMC questions

GSK is proud to partner with UNC to offer fellows the opportunity to develop the expertise necessary to pursue a rewarding career within Regulatory. This fellowship represents a unique opportunity for talented and ambitious individuals to accelerate their careers. GRA is committed to providing fellows leadership support, mentoring and development opportunities to help ensure they thrive and flourish. We look forward to working with diverse and emerging talent to help them become tomorrow’s great leaders.”

Jonathan LaCalamita
Vice President, US Regulatory Affairs & Advertising and Promotion

Sponsor

Kevin Fitzgerald, BSPharm
Senior Director, Specialty Therapeutic Group R&D Global Regulatory Affairs

CMC Fellows

Nhu Duong, PharmD
Second Year Fellow Calit2 NorthState University College of Pharmacy

Jessica Miller, PharmD
First Year Fellow UNC Eshelman School of Pharmacy

Sanni Rana, PharmD
Second Year Fellow Specialty Therapeutic Group UNC Eshelman School of Pharmacy

Faatimah Arshad, PharmD
First Year Fellow Oncology Therapeutic Group TTUHSC Jerry H. Hodge School of Pharmacy

Jessica Miller, PharmD
First Year Fellow UNC Eshelman School of Pharmacy

Nhi Duong, PharmD
Second Year Fellow Calit2 NorthState University College of Pharmacy

Bashir Idris, PharmD
First Year Fellow Specialty Therapeutic Group Virginia Commonwealth University School of Pharmacy

GSK is proud to partner with UNC to offer fellows the opportunity to develop the expertise necessary to pursue a rewarding career within Regulatory. This fellowship represents a unique opportunity for talented and ambitious individuals to accelerate their careers. GRA is committed to providing fellows leadership support, mentoring and development opportunities to help ensure they thrive and flourish. We look forward to working with diverse and emerging talent to help them become tomorrow’s great leaders.”

Program Director

Kevin Fitzgerald, BSPharm
Senior Director, Specialty Therapeutic Group R&D Global Regulatory Affairs
Pharmacokinetics/ Pharmacodynamics Fellowship

Fellowship Objectives

- Understand the nature and relevance of clinical data evaluations relative to drug development.
- Design and implement studies to examine drug absorption, drug disposition, pharmacodynamic endpoints and drug interactions in healthy human volunteers or diseased patient populations.
- Understand foundational concepts related to population PK/PD and physiologically-based PK modeling and simulation techniques.
- Understand important considerations in clinical trial design and the conduct of clinical investigations in specific patient populations (e.g., pediatrics).
- Perform PK/PD and statistical data analysis using relevant software packages.
- Prepare a manuscript, seminar and other scholarly vehicles for communication of scientific results.

At the UNC Eshelman School of Pharmacy, fellows will have the opportunity to:

- Engage in didactic and scholarly training via coursework in population and physiologically-based PK/PD modeling and simulation techniques.
- Coordinate and support clinical pharmacology, drug pharmacokinetic and metabolism studies and mathematical modeling with UNC Division of Pharmacotherapy and Experimental Therapeutics (DPET) faculty.
- Design, conduct and carry out data analysis of clinical pharmacology studies in the academic setting as part of the learning experience.

Faculty Members

- Derek Bartlett, Ph.D., Assistant Professor, Division of Pharmacotherapy and Experimental Therapeutics, UNC.
- Yanguang (Carter) Cao, Ph.D., Associate Professor, Division of Pharmacotherapy and Experimental Therapeutics, UNC.
- Julie Dumond, Pharm.D., M.S., Associate Professor, Division of Pharmacotherapy and Experimental Therapeutics, UNC.

Sponsor

Brandon Swift, PhD
Senior Director, Clinical Pharmacology, Modeling and Simulation, Clinical Pharmacology and Experimental Medicine, R&D, GSK

Fellows

- Victoría Etges Helfer, PhD, Second Year Fellow, Federal University of Rio Grande do Sul.
- Suzan Farhang-Sardroodi, PhD, First Year Fellow, University of Zanja, Iran.

At GSK within Clinical Pharmacology Modelling and Simulation (CPMS), fellows will have the opportunity to:

- Interact with multi-disciplinary teams to apply state-of-the-art quantitative methodologies to aid the development of compounds in the GSK portfolio, such as population PK/PD analyses, exposure-response, disease progression modeling and clinical trial simulations.
- Provide expertise to the design and analysis of first-time-in-human, proof-of-concept, drug-drug interaction or other clinical pharmacology studies.
- Contribute to modeling and simulation efforts for quantitative decision making to enhance study design, support candidate selection, provide dose rationale, and/or benchmark against competitor compounds.
Global Pharmacovigilance Fellowship

The GSK Global Pharmacovigilance Fellowship is a 2 year program that provides practical training and experience in identifying, managing, and communicating the safety profile of a product to enable informed benefit-risk decisions by uniting science, technology, and talent.

The fellowship program will bridge the gap from Doctor of Pharmacy graduate to industry professional by focusing on global patient safety and developing fundamental skills necessary for a successful career within the pharmaceutical industry.

Fellowship Objectives

• Gain an understanding of the role of global clinical safety and pharmacovigilance in the lifecycle of a pharmaceutical product including how safety data from pre-clinical studies, clinical studies, and post-marketing experience translates to use in a healthcare setting
• Contribute as a member of a safety review team to support the ongoing evaluation of the benefit/risk profile of an asset. Become an integrated member of the cross-functional matrix team providing clinical safety input for the clinical development program of an asset.
• Identify and evaluate potential safety concerns, assist in preparation of documentation and develop associated communication to inform healthcare providers and regulatory authorities.
• Obtain exposure to innovative technologies, methodologies and emerging data sources, such as Artificial Intelligence (AI) healthcare providers and regulatory authorities.
• Develop leadership and critical thinking skills to prepare for a successful career in clinical safety and pharmacovigilance following completion of the fellowship program.

The Fellow will spend equal time at the UNC Eshelman School of Pharmacy and GSK during the first year.

UNC: The Fellow will be paired with faculty conducting clinical research and will focus on a project with a safety element. Additionally, the Fellow will participate in coursework, professional development activities, and the Fellows Forum.

GSK: The Fellow will be exposed to various areas of pharmacovigilance with a primary focus on clinical roles and therapeutic areas throughout the product life cycle. The Fellow will be assigned a mentor who will facilitate learning opportunities in order to develop an understanding of pharmacovigilance practices, global regulations, and clinical development in order to apply these fundamentals to monitoring patient safety.

During the second year, the Fellow will spend the majority of time at GSK working in a concentrated therapeutic area. The Fellow will become part of a functional matrix team and will have the opportunity to interact with other departments within GSK, such as Clinical Development, Biostatistics and Regulatory Affairs to learn how Global Safety is incorporated throughout the organization. The Fellow will fully integrate into the role of a Safety Scientist contributing to the safety evaluation and risk management of an asset.

Sponsor
Peggy Webster, MD, MBA
Head of Vaccine Safety

Program Director
Lorrie Schifano, PharmD
Safety Evaluation and Risk Management (SERM) Head Oncology/Immunology

Preceptor
Amy Timberlake, PharmD
SERM Scientific Director Oncology/Immunology

Fellow
Kristina Parmeone, PharmD, MPH
First Year Fellow
UNC Eshelman School of Pharmacy
UNC GSK Fellowship Alumni
(Employed at GSK)

Keith Pappa
Head of Clinical Sciences, Chief Scientific and Medical Office, ViVi Clinical Research & Drug Development fellow 1985-1986

Lynn Henson
Senior Director, SERM, Central Safety Department, GSK Clinical Research & Drug Development fellow 1990-1992

Melissa Ellis
Director, SERM, Central Safety Department, GSK Clinical Research & Drug Development fellow 1994-1996

Susan Ford
Director, Clinical Pharmacology, GSK Pharmacokinetics & Pharmacodynamics fellow 2000-2002

Lakshmi Vasist
Director, Clinical Pharmacology, GSK Pharmacokinetics & Pharmacodynamics fellow 2004-2006

Justin Koteff
Director, Scientific Communications, Strategy & Medical Information, ViVi Clinical Research & Drug Development fellow 2009-2011

Christine Trezza
Director, Medical Governance & Operations, Global Medical Affairs, ViVi Clinical Research & Drug Development fellow 2013-2015

Jennifer Kim Cremer
Director, Clinical Development, Respiratory & Specialty, GSK Clinical Research & Drug Development fellow 2014-2016

Prani Paka
Scientific Director, Global Medical Affairs, Oncology, GSK Medical Affairs fellow 2016-2018

Hitesh Patel
Medical Director, Medical Affairs, GSK Medical Affairs fellow 2017-2019

Lauren Hothen
Director Medical Communications & Scientific Training Medical Affairs fellow 2018-2020

Eric Mui
Associate Director, CMC Regulatory Affairs, Development-ERA-Biopharm Development Projects Chemistry, Manufacturing, Controls (CMC) fellow 2019-2021

Fernando Carreño
Manager, Quantitative Clinical Pharmacology Oncology - Clinical Pharmacology, Modeling and Simulation (CPSM) Department Pharmacokinetics/Pharmacodynamics fellow 2019-2021

Lauren Xu
Associate Director, CMC Global Regulatory Affairs, GSK Chemistry, Manufacturing, and Controls (CMC) fellow 2020-2022

Deanna Rubin
Associate Director, Oncology Therapeutic Group, Global Regulatory Affairs, GSK Global Regulatory Affairs fellow 2020-2022

Darrian Proco
Associate Director, Gepotidacin, Medical Affairs, GSK Medical Affairs fellow 2020-2022

Stephanie Kim
Manager, Specialty Therapeutic Group, Global Regulatory Affairs, GSK Global Regulatory Affairs fellow 2021-2022

Haley Karpick
Manager, Oncology, Oncology Therapeutic Group, Global Regulatory Affairs, GSK Global Regulatory Affairs fellow 2021-2023

Michele Muir
Associate Medical Director, Gynecologic Malignancies, Medical Affairs, GSK Medical Affairs fellow 2021-2023

Employed at UNC

Denise Rhoney
Associate Dean for Curricular Innovation, PACE, UNC Eshelman School of Pharmacy
Clinical Research & Drug Development fellow 1993-1995

Craig R. Lee
Professor of Pharmacy, DPET, UNC Eshelman School of Pharmacy
Clinical Research & Drug Development fellow 2000-2002
Application and Eligibility

The UNC Eshelman School of Pharmacy and GSK Pharmaceutical Industry Fellowships commence in July 2024.

Applicants must submit an online application including a letter of interest, CV, unofficial transcript, and 3 letters of recommendation.

Interviews will be arranged virtually for selected candidates.

Visit http://pharmacydpetfellowships.web.unc.edu for application instructions and deadlines.

Early applications are highly encouraged.

US Medical Affairs, Global Regulatory Affairs, PK/ PD, and Global Pharmacovigilance